Theravance Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $107.5 | $64.4 | $57.4 | $51.3 | $55.3 |
| Operating income | -$3.6 | -$46.9 | -$56.0 | -$92.0 | -$257.8 |
| Net income | $105.9 | -$56.4 | -$55.2 | $872.1 | -$199.4 |
| Cash Flow Statement | |||||
| Free cash flow | $238.5 | -$11.9 | -$29.5 | -$187.6 | -$211.3 |
| Share repurchases | — | $0.4 | $197.1 | $128.8 | — |
Shares outstanding 51.6M · Free float 38.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.